C2 and Mr K discuss the recent executive order (because why go through the established US form of government when you can wage a war and impose tariffs without Congress or oversight), enacted on 4/20, which accelerates research and expands access to therapies for post-traumatic stress disorder (PTSD).

There was also a noticeable bump, on 4/20, for psychedelic drug manufacturers like:

Compass Pathways (CMPS), a biotech company and makers of COMP360 a magic mushroom-based drug that treats depression and is in phase 3 and phase 2 trials, hailing out of London, England, jumped as high as 53%.

Atai Beckley (ATAI), a clinical-stage biopharmaceutical company based out of New York, New York gained 37% at one point on 4/20.

Definium Therapeutics (DFTX), a clinical biopharmaceutical company developing drugs to combat anxiety disorde ...